Epithelial-to-mesenchymal transition contributes to the downregulation of progesterone receptor expression in endometriosis lesions

Lijuan Ma a,b, Thomas Andrieu a,b, Brett McKinnon a,b, Lea Duempelmann a,b, Ren-Wang Peng b,c, Carlos Wotzkow b, Christoph Müller d, Michael D. Mueller a,b

a Department of Gynecology and Gynecological Oncology, Inselspital, Bern University Hospital, University of Bern, Friedbuehlstrasse 19, 3010, Bern, Switzerland
b Department for BioMedical Research (DBMR), University of Bern, Murtenstrasse 35, 3008, Bern, Switzerland
c Department of General Thoracic Surgery, Inselspital, Bern University Hospital, Murtenstrasse 50, 3008, Bern, Switzerland
d Institute of Pathology, University of Bern, Murtenstrasse 31, 3008, Bern, Switzerland

ARTICLE INFO

Keywords:
- Progesterone receptor
- EMT
- Endometriosis
- SNAI
- Progesterone resistance

ABSTRACT

Endometriosis is a common, estrogen-dependent disease, in which endometrial tissue grows in the peritoneal cavity. These lesions often express low levels of progesterone receptors (PR), which potentially play an important role in the insufficient response to progestin treatment. Here, we uncover an interconnection between the downregulated PR expression and the epithelial-to-mesenchymal transition (EMT) in endometriotic lesions. The majority of ectopic epithelial glands (93.1 %, n = 67/72) display heterogeneous states of EMT by immunohistochemistry staining. Interestingly, low PR expression associated with high N-cadherin expression, a hallmark of EMT. In order to gain mechanistic insights, we performed in vitro functional assays with the endometriotic epithelial cell lines EM-osis and 12Z. TGF-β-induced EMT, marked by elevations of CDH2 and SNAI1/2, led to a significant downregulation of PR gene expression in both cell lines. In contrast, silencing of SNAI1 in EM-osis and of SNA1 plus SNAI2 in 12Z elevated PR gene expression significantly. We found that not only in vitro, but also in the epithelial component of endometriotic lesions strong expression of SNAI1/2 concurred with weak expression of PR. In summary, these results suggested the negative correlation association of the heterogeneous states of EMT and suppressed PR expression in endometriotic lesions. Our functional assays indicate that EMT contributes to the downregulation of PR expression via the upregulation of EMT-TFs, like SNAI1 and SNAI2, which may ultimately lead to progesterone resistance.

1. Introduction

Endometriosis is a common gynecological disease affecting around 6–10 % of women of reproductive age, causing pelvic pain and infertility [1]. Characterized by the presence of endometrial epithelial and stroma cells outside the uterine cavity, the endometriosis lesion still depends on estrogen to grow [2]. Consequently, the basic rationale of the current medical therapies for endometriosis is to reduce estrogen level.

Progestins, known for their anti-estrogenic effects resulting in endometrial decidualization, and inhibit the surges of gonadotropin-releasing hormone / luteinizing hormone [3,4] and thereby block the ovulation. They also locally reduce estrogenic effects by stimulating the transcription of the enzyme 17β-HSD2 [5], which catalyzes the conversion of the highly active estrogen estradiol (E2) to less potent estrone. Thus, progestins can suppress the endometrial proliferation and induce apoptosis, consequently, impeding the proliferation of the endometriosis lesions. However, the treatment failure for endometriosis patients under progestin-based therapy is increasingly noticed, potentially involving an attenuated response to progestin treatments termed progesterone resistance [6,7]. Progestins exert their effects by binding to progesterone receptors (PR). Suppressed PR expression has been preferentially reported in ectopic lesions [8,9]. Several reports indicated that PR reduction could impede the progestin therapy response [5,10,11]. However, the mechanisms leading to the reduced PR expression in endometriosis remain largely unknown. Comprehensive studies and reviews suggested that the downregulation of PR may be a consequence of the exposure to an altered peritoneal cavity microenvironment [7,12,13]. It is important to understand the specific mechanisms which may
cause loss of PR expression and whether it contributes to the resistance to progesterin therapy.

Epithelial-mesenchymal transition (EMT) is a biological process during which epithelial cells lose the epithelial features and instead gain properties of mesenchymal cells. The hallmark of EMT is the so-called “Cadherin switch”, marked by downregulation of E-cadherin and upregulation of N-cadherin [14–16]. E-cadherin is the epithelial marker, which supports columnar morphology, bud outgrowth and luminal structure [15,16]. N-cadherin is the mesenchymal marker, which was reported to promote aggregation and collective cell migration that facilitates invasion and metastasis [14]. A number of studies reported EMT-inducing transcription factors (EMT-TFs) to promote the EMT process through various signaling cascades [17–19]. Examples for such EMT-TFs are Snail family transcriptional repressor 1 (SNAI1), Snail family transcriptional repressor 2 (SNAI2, also known as slug) and Zinc Finger E-Box Binding Homeobox 1 (ZEB1) [19,20]. New insights encourage the re-investigation of these tissue-specific EMT-TFs and their pleiotropic roles in physiological and pathological conditions [18,21]. Particularly in endometriosis, EMT related processes were significantly upregulated in ectopic endometrial lesions compared to eutopic endometrium [22,23]. Therefore, EMT might participate in the pathogenesis of endometriosis [24]. EMT can be induced by various growth and differentiation factors. Among those, TGF-β is recognized as a major inducer of EMT, which increases the transcription factors SNAI1/2 and ZEB1/2 through a well-orchestrated transcription program [25,26]. Interestingly, an increased TGF-β concentrations have been frequently observed in endometriosis patients in peritoneum and peritoneal fluid surrounding endometriosis tissues [27,28].

To our knowledge, there are no studies that investigated EMT as the potential cause for the downregulation of progesterone receptors in endometriosis lesions. Hence, the purpose of this study was to investigate the association between PR expression and EMT in endometriosis and to explore the potential mechanisms of downregulation of PR in ectopic endometrial cells.

2. Materials and methods

2.1. Patient tissue handling

All endometriosis ectopic lesions have been collected following a protocol approved by the local ethical committee. The lesions were categorized as superficial peritoneal endometriosis (SUP), endometrioma (OMA) or deeply infiltrating endometriosis (DIE). The diagnosis of endometriosis was confirmed by pathologists. Menstrual cycle, potential hormonal treatment, endometriosis subtypes and number of endometriosis cell lines were summarized in the supplementary Table 2. Samples fixed with formalin were stored in 70% ethanol at 4 °C for 1–4 min following 30 min streptavidin-horseradish peroxidase (ab7403, Abcam, USA) incubation and removal. Hematoxylin was applied as counterstaining.

For IF, the tissue sections were at 95 °C in citrate buffer (pH = 6) for 15 min for antigen retrieval. Then they were incubated with the primary antibodies overnight at 4 °C and the fluorophore-conjugated secondary antibodies were incubated at RT for 1 h. The cell nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI, D9564, Sigma-Aldrich, USA).

As the negative controls, ectopic tissue samples were incubated with blocking buffer with 3% goat serum instead of primary antibodies.

Panoramic scanner (250 Flash II, 3DHISTECH) was used for capturing the pictures from IF and IHC. QuPath (version 2.2) was used for detecting the positive and negative cells according to the uniformed thresholds, and for capturing the fluorescence intensities. All of the ectopic epithelial glands were identified and the percentage of positive cells per gland was calculated accordingly.

2.3. Cell culture and treatment

122 and EM’osis cell lines were both obtained in January of 2013 as the generous gifts from collaborating labs [29,30]. Both cell lines were passaged in IMDM supplemented with 10% FCS. 122 at passage 50–51 of and EM’osis at passage 14–15 were used in our experiments. These cells were negative for mycoplasma infection (MycoAlert, Lonza, Switzerland). Transforming growth factor beta 1 (TGF-β1, AF-100-21C, Peprotech) was prepared in PBS and S431542 (1614, TOCRIS), a selective inhibitor of TGF-β1 receptor in DMSO. Cells were cultured in 6-well plate in phenol red-free IMDM supplemented with 5% charcoal-stripped FBS (A33821-1, Gibco) at the density of 2 × 10^4 cells well for 122 and EM’osis until 70–80% confluence. To determine the IC50 of TGF-β1, cells were treated in triplicates with doses ranging from 0.125 to 1 ng/mL. The involvement of TGF-β1 receptor was assessed with a co-treatment of TGF-β1 (0.5–1 ng/mL) and S431542 (100 nM). Control groups were treated with an equivalent volume of vehicles. The cells were harvested after 24 h treatment by trypsinization and RNA isolated as described below. All cell cultures were maintained at 37 °C in a 5% CO2 atmosphere.

2.4. Quantitative real-time-polymerase chain reaction (qRT-PCR)

RNA extraction was performed with the ReliaPrep™ RNA Miniprep Systems (Z6011, Promega, USA) according to the manufacturer’s instructions. One microgram of RNA was reverse transcribed in a final volume of 20 μl with RNase inhibitor (N261A, Promega, USA), reverse transcriptase enzyme (M1708, Promega, USA), nucleotide mix (U1518, Promega, USA), and random primers (C118A, Promega, USA). The resulting cDNA was diluted 1:10. Real-time quantitative polymerase chain reaction (qRT-PCR) using Taqman Fast Advanced Master Mix (4444556 Thermofisher, USA) and TaqMan® gene expression arrays for PGR (gene encoding PR, Hs01556702_m1), CD2H (gene encoding N-cadherin, Hs00983056_m1), SNAI1 (Hs01195591_m1), SNAI2 (Hs0000161904_m1), and ZEB1 (Hs00232783_m1). The qRT-PCR was performed on an Applied Biosystems 7500 fast instrument (ThermoFisher, USA), with the following conditions: 95 °C for 5 min, followed by 40 cycles of 95 °C for 5 seconds and 60 °C for 10 s. Multiple reference genes [18S rRNA (Hs99999901_s1), GAPDH (Hs00265670_s1), beta-actin (Hs01060665_g1), YWHAZ (Hs03044281_g1), UBC (Hs00824723_m1)] were determined the M value of geNorm by Qbase plus software (Biogazelle, Belgium) to compare their stability across the cell lines with/without TGF-β1 treatments. Considering the expression level, YWHAZ, one of the most stable reference genes was employed for normalization among the employed cell types and conditions (supplementary Fig. 1). The comparative cycle threshold (2−ΔΔCt) method was used to assess changes in gene expression.
2.5. Knockdown with small interfering RNA against SNAI1/2

EM’osis was transfected with 20 nM of siRNA against SNAI1 (s13185, Silencer Select siRNA, Ambion Inc., USA) or scrambled control siRNA (4390844, Silencer Select Negative Control #1 siRNA, Ambion Inc., USA). 12Z cells were transfected with 20 nM of a pool of equal proportion of 3 siRNA against SNAI1 (SR304489, Human siRNA Oligo Duplex, Locus ID 6615, Origene, USA), as well as SNAI2 (Silencer siRNA Oligo Duplex, Locus ID 106954, Ambion Inc., USA) or scrambled control from the same set of si-SNAI1 (SR304489, Human siRNA Oligo Duplex, Locus ID 6615, Origene USA). One μl lipofectamine RNAiMAX as transfection reagent (13778075, Thermofisher, USA) was used for one well of 24-well plate under 80 % confluent cells, according to vendor’s instructions. RNA was isolated 48 h after transfection.

2.6. Statistical analysis

All statistical analyses were performed in Graphpad Prism version 8.0. Mann-Whitney test was used when the data were not normally distributed, i.e. to compare PR expression between N-cadherin positive/ negative groups. One-way ANOVA was used to identify the difference of gene expression between different treatment groups in the in vitro models. P <0.05 was considered statistically significant.

3. Results

3.1. Various EMT states can be detected within ectopic lesions

The protein expressions of E-cadherin and N-cadherin in ectopic epithelial cells was quantified by IHC in three subtypes of endometriosis: endometrioma (n = 4), superficial endometriosis (n = 3) and deeply infiltrating endometriosis (n = 4). From these 11 cases a total of 72 epithelial glands were characterized and their profiles are summarized in supplementary Table 2. Interestingly, most of the analyzed ectopic glands displayed various states of EMT, characterized by either reduced EMT in endometriosis and other model systems [24, 25]. When applied to ectopic epithelial derived cell lines (12Z and EM’osis), TGF-β1 indeed increased the expression of CDH2 and SNAI1, both hallmarks for EMT, to ectopic epithelial cells (Fig. 1). Only a small fraction of the glands (5/72, 6.9 %) contained exclusively differentiated epithelial cells (100 % E-cadherin and 0 % N-cadherin positive cells) (Fig. 1B).

3.2. High N-cadherin at protein expression is concurrent with low PR protein expression at in ectopic lesions

IHC staining of serial sections revealed a rather low and heterogeneous protein expression of PR with a median of 10.5 % PR positive epithelial cells per gland. Due to the impact of hormone on PR expression, only the cases without hormonal treatment were considered in further analysis. Within this population (non-hormone users, n = 6; glands, n = 50, Supplementary Table 2), we observed that PR expression was significantly lower in N-cadherin positive epithelial glands compared to that in N-cadherin negative epithelial glands (median 0.00 vs 12.09, P = 0.028, Fig. 2A). This negative association is illustrated in the representative immunostaining shown in Fig. 2B and C, where PR expression was stronger in the epithelial cells with lower N-cadherin expression. Immunofluorescence staining of ectopic lesions confirms that the expression of N-cadherin and PR is distributed in a mutually exclusive manner in ectopic glands (Fig. 2D-G).

3.3. EMT inducing transcription factors inhibit PGR gene expression in vitro

We next investigated how the induced EMT alters the PGR gene expression. The TGF-β1 pathway plays a crucial role in the induction of EMT in endometriosis and other model systems [24,25]. When applied to ectopic epithelial derived cell lines (12Z and EM’osis), TGF-β1 indeed increased the expression of CDH2 and SNAI1, both hallmarks for EMT, in a dose depend manner (Fig. 3A and B). In EM’osis cells, CDH2 expression was only minimally altered, most likely due to its mesenchymal status characterized by a high expression level of CDH2 and its typical cell morphology. In line with the inverse correlation reported in ectopic lesion, PGR gene expression is decreased following TGF-β1 induced EMT. The downregulation of PGR under 24 h TGF-β1 treatment is statistically significant in EM’osis and 12Z cells (P < 0.05). As expected, TGF-β1 receptor inhibitor abrogated the TGF-β1 induced...
downregulation of PGR, and even upregulated PGR significantly in EM’osis cells (\( P < 0.001 \)) (Fig. 3 C and D). SNAI1 was increased by TGF-\( \beta \)1 treatment significantly in both cell lines (\( P < 0.001 \)). In addition, SNAI2 upregulation under TGF-\( \beta \)1 treatment was only observed in the 12Z cell line (\( P < 0.05 \)). ZEB1, another core EMT promoting TF, did not increase under TGF-\( \beta \)1 treatment in either cell line (Fig. 3 C and D).

### 3.4. EMT related PGR repression is SNAI1/2 dependent

12Z and EM’osis cells were transfected with siRNA targeting SNAI1 and SNAI2 to evaluate the role of these TFs in the EMT dependent suppression of PGR. In EM’osis cells, knockdown of SNAI1 reaching 58.7% reduction at 48 h after transfection, resulted in a significant increase of PGR expression (1.26 fold, \( P = 0.028 \), Fig. 4 A). In 12Z cells, a
combined knockdown of SNAI1 and SNAI2 was used, since both factors increased after TGF-β1 treatment (Fig. 4B). The use of this siRNA mixture (siRNA against SNAI1 and siRNA against SNAI2) was also supported by the fact that a compensatory mechanism apparently takes place when SNAI1 or 2 are downregulated independently (supplementary Fig. 3). Indeed, SNAI2 downregulation led surprisingly to an increase of SNAI1 mRNA expression (and vice versa) in 12Z (supplementary Fig. 3). Hence, the siRNA mixture represented the most efficient way to keep both SNAI1 and 2 at low levels. In fact, in 12Z, the combined knockdown decreased by 48.6 % the mRNA level of SNAI2 while preventing the expected increase of SNAI1 (siSNAI1 2, Fig. 4B).

All in all, SNAI silencing in 12Z led to a significant elevation of PGR expression (1.39 fold, \(P = 0.0002\), Fig. 4B), as found in EM’osis cells.

Next, we performed an \textit{in silico} analysis of the PGR to identify a possible cause for our observed downregulation of the PGR at mRNA level. This analysis revealed 8 potential cis–acting elements (CANNTG, E-box) for both SNAI1 and SNAI2, listed in supplementary Table 3. Altogether, these \textit{in vitro} experiments demonstrated that TGF-β1 induced EMT, characterized by an increase of mesenchymal markers (CDH2 and SNAI1/2), importantly, is accompanied by SNAI dependent PGR downregulation.

### 3.5. SNAI1/2 and PR expressions are negatively correlated in DIE ectopic lesions

We further verified the protein expression level of SNAI1/2 in ectopic lesions by IF (Fig. 4C–F). We found that the high protein expression of SNAI1/2 in the ectopic epithelial cells associates with the low protein expression of PR, while the low protein expression of SNAI1/2 was concurrent with the high protein expression of PR.

And we further used Qupath to detect the intensity of immunofluorescence signals of SNAI1/2 and PR from 647 epithelial cells from 6
SNAI1 and SNAI2 as the most affected TFs during TGF-β-high N-cadherin expression, illustrated in immunofluorescence epithelial glands (Fig. 2A). The low PR expression is concurrent with positive epithelial glands compared to that in N-cadherin negative likely triggered by the altered pelvic microenvironment [32]. We further found that PR expression was significantly lower in N-cadherin glands lose E-cadherin expression compared to eutopic endometrium, supporting our results from the study had been suggested in either study.

Meanwhile, immunohistochemistry revealed that most of the ectopic glands lose E-cadherin expression (n = 48/72) and partially expressing N-cadherin (n = 18/72). In agreement with a previous report, these partial EMT states are present in most ectopic epithelial glands, being likely triggered by the altered pelvic microenvironment [32]. We further found out the PR expression was significantly lower in N-cadherin positive epithelial glands compared to that in N-cadherin negative epithelial glands (Fig. 2A). The low PR expression is concurrent with high N-cadherin expression, illustrated in immunofluorescence co-staining of PR and N-cadherin (Fig. 2D–G). This is in line with a previous report from Liu et al., who found that PR-B, a dominant isoform of PR in endometrium, negatively correlated with EMT markers in endometriosis subtypes.

Our study revealed a potential negative association between PR and N-cadherin at the protein level. By employing endometriotic cell lines, we verified that TGF-β1-induced EMT downregulated PGR gene expression. Furthermore, we found that SNAI1/2, two core EMT-TFs, play the important roles in regulation of PGR. Most importantly, the results were supported in situ, showing a negative correlation between SNAI1/2 and PR protein expression in endometriosis lesions.

We observed that PR was absent in the individual endometriotic epithelial cells, which was broadly mentioned previously by multiple studies [8,9,11,31]. Using the open-source software QuPath that automatically quantified the staining intensity of individual cells from the immunohistochemistry, we calculated the percentage of positive cells per epithelial gland. A representative example of the QuPath analysis is shown in supplementary Fig. 2. Interestingly and importantly, the expression of PR is heterogeneous intrasubject. This finding is consistent with a recent report [11]. Due to the limited sample size, we refrained from performing a subgroup analysis on PR expression across different endometriosis subtypes.

In line with other reports [40–42], knockdown of SNAI1 by siRNA in EM ois cell lines was only moderately efficient, but nevertheless resulted in a consistent upregulation of PGR. These results suggest that SNAI1/2 mediate EMT, which induces PGR repression either by acting directly on the promoter or through an indirect mechanism. SNAI1/2 was previously reported to repress gene expression by binding to its motif constituting a subset of E-box [43]. Interestingly, each PR promoter contains four E-box motifs. Thus, it is plausible to postulate that SNAI1/2 suppresses PGR transcription by binding to the gene promoters.

As the difficulty of setting up culture condition for primary epithelial cells, we employed immortalized endometriotic epithelial cell lines, 12Z and EM-ois. However, we observed both cell lines have lost their epithelial phenotype in culture, especially EM-ois cells. They showed a typical mesenchymal phenotype under the microscope, recognizable by a spindle like shape. The protein expression of E-cadherin was not detectable, instead N-cadherin was strongly expressed as previously reported for 12Z [30]. PR expressions at protein level in both cell lines are also not detectable, which are possibly natural results due to the mesenchymal status. In another hand, our study conclusions have been therefore restricted to the transcriptomic level. However, the negative correlation between SNAI1/2 and PR could be confirmed by immunofluorescent double staining in patient samples. This is in line with the strong protein expression of SNAI1 in ectopic lesions [37,44,45].

5. Conclusions and outlook

Our study indicates that the clinically relevant, but so far unrevealed downregulation of PR could be the consequence of the heterogeneous EMT states in endometriosis lesions. Since the altered PR expression in ectopic lesions might indicate the attenuated response to progesterin-based therapy, we propose that EMT participates in progesterin treatment resistance and/or failure. In our study, SNAI1/2 silencing concurrently reversed EMT and increased PGR expression. This highlights the potential role of EMT related factors in the downregulation of PGR. Ultimately, it will be interesting to explore the effect of relevant compounds, such as SNAI inhibitors, to reverse EMT in endometriosis. This might lead to the establishment of a novel adjuvant therapy for endometriosis patients with progesterone resistance.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors thanks to the funding from Department of Gynecology and Gynecological Oncology, Inselspital. The authors thank the clinicians from Frauen Klinik of Inselspital for supporting on obtaining the patients’ samples. The authors thank Haitang Yang, Li Hai, Lan Zhang, Anne Vacher, and P.D. Thomas Michael Marti from DBMR, University of Bern, for the assistance and suggestions on experiments. The authors thank Prof. Rory Johnson from Department of Medical Oncology,
The authors thank the open-source software QuPath.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.jsbmb.2021.105943.

References

[1] R.O. Burney, L.C. Giudice, Pathogenesis and pathophysiology of endometriosis, Fertil. Steril. 98 (3) (2012) 511–519.
[2] L.C. Giudice, L.C. Kao, Endometriosis, Lancet 364 (9447) (2004) 1789–1799.
[3] T.A. Richter, et al., Progesterone can block the preovulatory gonadotropin-releasing hormone/luteinising hormone surge in the ewe by a direct inhibitory action on oestriol-responsive cells within the hypothalamus, J. Neuroendocrinol. 17 (3) (2005) 161–169.
[4] T.A. Richter, J.E. Robinson, N.P. Evans, Progesterone blocks the estradiol-stimulated luteinizing hormone surge by disrupting activation in response to a stimulatory estradiol signal in the ewe, Biol. Reprod. 67 (1) (2002) 119–125.
[5] S. Yang, et al., Stromal Pbs mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2, Mol. Endocrinol. 15 (12) (2001) 2093–2103.
[6] B.G. Patel, et al., Progesterone resistance in endometriosis: origins, consequences and interventions, Acta Obstet. Gynecol. Scand. 96 (6) (2017) 623–632.
[7] M.K. Eyster, et al., DNA microarray analysis of gene expression markers of adenomyosis, Hum. Reprod. 22 (3) (2008) 716–727.
[8] L. Konrad, et al., Progesterone regulates matrix metalloproteinases (MMP) in human endometrial stromal cells, Mol. Endocrinol. 116 (2013) 317–326.
[9] S.E. Bulun, et al., Estrogen receptor-beta, estrogen receptor-alpha, and progesterone receptor forms A and B. generate transcripts encoding the two functionally different human progesterone receptor isoforms, Endocrinology 150 (12), 6451-6465.
[10] R.O. Burney, L.C. Giudice, Pathogenesis and pathophysiology of endometriosis, Fertil. Steril. 98 (3) (2012) 511–519.
[11] B. McKinnon, M. Mueller, G. Montgomery, Progesterone resistance in endometriosis: an acquired property? Trends Endocrinol. Metab. 23 (3) (2012) 535–546.
[12] K.M. Eyster, et al., DNA microarray analysis of gene expression markers of adenomyosis, Hum. Reprod. 22 (3) (2008) 716–727.
[13] S. Matsuzaki, et al., Differential expression of genes in eutopic and ectopic endometrium from patients with ovarian endometriosis, Fertil. Steril. 86 (3) (2006) 548–553.
[14] R.B. Hazan, et al., Cadherin switch in tumor progression, Ann. N. Y. Acad. Sci. 1014 (2004) 155–163.
[15] M.J. Wheelock, et al., Cadherin switching, J. Cell Sci. 121 (Pt 6) (2008) 727–735.
[16] A. Gheldof, G. Berx, Cadherins and epithelial-to-mesenchymal transition, Prog. Mol. Biol. Transl. Sci. 116 (2013) 317–336.
[17] T.A. Martin, et al., Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer, Ann. Surg. Oncol. 12 (6) (2005) 488–496.
[18] B. McKinnon, M. Mueller, G. Montgomery, Progesterone resistance in endometriosis: an acquired property? Trends Endocrinol. Metab. 23 (3) (2012) 535–546.
[19] R. Nakamura, et al., Reciprocal expression of Slug and Snail in human oral cancer carcinoma, Cancer Med. 8 (9) (2019) 4380–4388.
[20] A. Gheldof, G. Berx, Cadherins and epithelial-to-mesenchymal transition, Prog. Mol. Biol. Transl. Sci. 116 (2013) 317–336.
[21] M. Kajita, K.N. McClinic, P.A. Wade, Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress, Mol. Cell. Biol. 24 (17) (2004) 7559–7566.
[22] S. Matsuzaki, et al., Enhanced epithelial to mesenchymal transition (EMT) and upregulated MYC in ectopic lesions contribute independently to endometriosis, Reprod. Biol. Endocrinol. 13 (2015) 75.
[23] S. Matsuzaki, C. Darcha, Epithelial to mesenchymal transition-like and mesenchymal to epithelial transition-like processes might be involved in the pathogenesis of pelvic endometriosis, Hum. Reprod. 27 (3) (2012) 712–721.
[24] Y. Yang, Epithelial-to-mesenchymal Transition in the Development of Endometriosis, 2017.
[25] J. Xu, S. Lamouille, R. Derynck, TGF-beta-induced epithelial to mesenchymal transition, Cell Res. 19 (2) (2009) 156–172.
[26] Y. Hao, D. Baker, P. Ten Dijke, TGF-β-Mediated epithelial-mesenchymal transition and Cancer metastasis, Int. J. Mol. Sci. 20 (11) (2019).
[27] C.M. Ryma, et al., Increased peritoneal and endometrial gene expression of biologically relevant cytokines and growth factors during the menstrual phase in women with endometriosis, Fertil. Steril. 85 (6) (2006) 1667–1675.
[28] A. Pizzo, et al., Behaviour of cytokine levels in serum and peritoneal fluid of women with endometriosis, Gynecol. Obstet. Invest. 54 (2) (2002) 82–87.
[29] Y. Bono, et al., Creation of immortalised epithelial cells from ovarian endometrioma, Br. J. Cancer 106 (6) (2012) 1205–1213.
[30] A. Zeitvogel, R. Baumann, A. Starzinski-Powitz, Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model, Am. J. Pathol. 159 (5) (2001) 1839–1852.
[31] G.R. Attia, et al., Progesterone receptor isoform A but not B is expressed in endometriosis, J. Clin. Endocrinol. Metab. 85 (8) (2000) 2897–2902.
[32] S. Matsuzaki, C. Darcha, Epithelial to mesenchymal transition in endometriosis-when does it happen? J. Clin. Med. 9 (6) (2020).
[33] X. Liu, et al., Corroborating evidence for platelet-induced epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis, Hum. Reprod. 31 (4) (2016) 734–749.
[34] Q. Zhou, et al., DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma, Cancer Med. 8 (9) (2019) 4380–4388.
[35] H. Inoh, et al., Transforming growth factor beta1 attenuates expression of both the progesterone receptor and Dickkopf in differentiated human endometrial stromal cells, Mol. Endocrinol. 22 (3) (2008) 716–728.
[36] H. Inoh, et al., Transforming growth factor beta1 (TGFbeta1) and progesterone regulate matrix metalloproteinases (MMP) in human endometrial stromal cells, J. Clin. Endocrinol. Metab. 97 (6) (2012) E888–97.
[37] X. Cai, et al., Reduced expression of eukaryotic translation initiation factor 3 subunit e and its possible involvement in the epithelial-mesenchymal transition in endometriosis, Reprod. Sci. 25 (1) (2018) 102–109.
[38] M.P. Stemmler, et al., Non-redundant functions of EMT transcription factors, Nat. Cell Biol. 21 (1) (2019) 102–112.
[39] R. Nakamura, et al., Reciprocal expression of Slug and Snail in human oral cancer cells, PLoS One 13 (7) (2018) e0199442.
[40] M. Funaya, et al., ZEB1 expression is a potential indicator of invasive endometriosis, Acta Obstet. Gynecol. Scand. 96 (9) (2017) 1128–1135.

Further reading

[46] Kastner, P., et al., Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J., 1990, 9 (5): p. 1603-1614.